Mingzhao Xing

List of Publications by Year
in descending order

134 papers	15,810 citations	19657 61 h-index	16650 123 g-index
136 all docs	136 docs citations	136 times ranked	10654 citing authors

#	Article	IF	Citations
1	Molecular pathogenesis and mechanisms of thyroid cancer. Nature Reviews Cancer, 2013, 13, 184-199.	28.4	1,125
2	BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6373-6379.	3.6	893
3	BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications. Endocrine Reviews, 2007, 28, 742-762.	20.1	857
4	BRAF Mutation in Papillary Thyroid Carcinoma. Journal of the National Cancer Institute, 2003, 95, 625-627.	6.3	849
5	Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer. JAMA - Journal of the American Medical Association, 2013, 309, 1493.	7.4	775
6	<i>BRAF</i> V600E and <i>TERT</i> Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence. Journal of Clinical Oncology, 2014, 32, 2718-2726.	1.6	595
7	Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocrine-Related Cancer, 2013, 20, 603-610.	3.1	500
8	Progress in molecular-based management of differentiated thyroid cancer. Lancet, The, 2013, 381, 1058-1069.	13.7	496
9	Association Between <i>BRAF</i> V600E Mutation and Recurrence of Papillary Thyroid Cancer. Journal of Clinical Oncology, 2015, 33, 42-50.	1.6	448
10	Genetic Alterations and Their Relationship in the Phosphatidylinositol 3-Kinase/Akt Pathway in Thyroid Cancer. Clinical Cancer Research, 2007, 13, 1161-1170.	7.0	362
11	Highly Prevalent Genetic Alterations in Receptor Tyrosine Kinases and Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase Pathways in Anaplastic and Follicular Thyroid Cancers. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3106-3116.	3.6	349
12	TERT promoter mutations in thyroid cancer. Endocrine-Related Cancer, 2016, 23, R143-R155.	3.1	301
13	BRAF Mutation in Papillary Thyroid Cancer and Its Value in Tailoring Initial Treatment. Medicine (United States), 2012, 91, 274-286.	1.0	264
14	<i>TERT</i>Promoter Mutations and Their Association with<i>BRAF</i>V600E Mutation and Aggressive Clinicopathological Characteristics of Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1130-E1136.	3.6	262
15	Genetic Alterations in the Phosphatidylinositol-3 Kinase/Akt Pathway in Thyroid Cancer. Thyroid, 2010, 20, 697-706.	4.5	258
16	<i>BRAF</i> Mutation Testing of Thyroid Fine-Needle Aspiration Biopsy Specimens for Preoperative Risk Stratification in Papillary Thyroid Cancer. Journal of Clinical Oncology, 2009, 27, 2977-2982.	1.6	256
17	Detection of BRAF Mutation on Fine Needle Aspiration Biopsy Specimens: A New Diagnostic Tool for Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2867-2872.	3.6	239
18	Mortality Risk Stratification by Combining <i>BRAF </i>V600E and <i>TERT</i> Promoter Mutations in Papillary Thyroid Cancer. JAMA Oncology, 2017, 3, 202.	7.1	217

#	Article	IF	Citations
19	Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the <i>ALK</i> Gene. Cancer Research, 2011, 71, 4403-4411.	0.9	190
20	Uncommon Mutation, but Common Amplifications, of thePIK3CAGene in Thyroid Tumors. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4688-4693.	3.6	189
21	Association of High Iodine Intake with the T1799A BRAF Mutation in Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1612-1617.	3.6	189
22	Prognostic utility of BRAF mutation in papillary thyroid cancer. Molecular and Cellular Endocrinology, 2010, 321, 86-93.	3.2	188
23	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 264-274.	3.6	179
24	Gene Methylation in Thyroid Tumorigenesis. Endocrinology, 2007, 148, 948-953.	2.8	168
25	Suppression of BRAF/MEK/MAP Kinase Pathway Restores Expression of Iodide-Metabolizing Genes in Thyroid Cells Expressing the V600E BRAF Mutant. Clinical Cancer Research, 2007, 13, 1341-1349.	7.0	166
26	C9ORF72 GGGGCC repeat-associated non-AUG translation is upregulated by stress through eIF2Î± phosphorylation. Nature Communications, 2018, 9, 51.	12.8	166
27	Recent incidences and differential trends of thyroid cancer in the USA. Endocrine-Related Cancer, 2016, 23, 313-322.	3.1	164
28	Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. International Journal of Cancer, 2006, 119, 2322-2329.	5.1	162
29	High Prevalence and Mutual Exclusivity of Genetic Alterations in the Phosphatidylinositol-3-Kinase/Akt Pathway in Thyroid Tumors. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2387-2390.	3.6	154
30	Early Occurrence of <i>RASSF1A</i> Hypermethylation and Its Mutual Exclusion with <i>BRAF</i> Mutation in Thyroid Tumorigenesis. Cancer Research, 2004, 64, 1664-1668.	0.9	142
31	Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer. Nature Communications, 2018, 9, 579.	12.8	140
32	Association of <i>PTEN</i> gene methylation with genetic alterations in the phosphatidylinositol 3â€kinase/AKT signaling pathway in thyroid tumors. Cancer, 2008, 113, 2440-2447.	4.1	138
33	Highly prevalent<i>TERT</i>promoter mutations in bladder cancer and glioblastoma. Cell Cycle, 2013, 12, 1637-1638.	2.6	123
34	Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochemical and Biophysical Research Communications, 2010, 393, 555-559.	2.1	122
35	High Prevalence and Possible de Novo Formation of BRAF Mutation in Metastasized Papillary Thyroid Cancer in Lymph Nodes. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5265-5269.	3.6	114
36	BRAF V600E Maintains Proliferation, Transformation, and Tumorigenicity of BRAF-Mutant Papillary Thyroid Cancer Cells. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2264-2271.	3.6	110

#	Article	IF	Citations
37	<i>BRAF</i>and<i>TERT</i>promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients. Oncotarget, 2016, 7, 18346-18355.	1.8	109
38	CRISPR-Cas9 Screens Identify the RNA Helicase DDX3X as a Repressor of C9ORF72 (GGGGCC)n Repeat-Associated Non-AUG Translation. Neuron, 2019, 104, 885-898.e8.	8.1	107
39	Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Research, 2003, 63, 2316-21.	0.9	107
40	Induction of Thyroid Gene Expression and Radioiodine Uptake in Thyroid Cancer Cells by Targeting Major Signaling Pathways. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 820-828.	3.6	104
41	BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis. Endocrine-Related Cancer, 2015, 22, 159-168.	3.1	102
42	Patient Ageâ€"Associated Mortality Risk Is Differentiated by <i>BRAF</i> V600E Status in Papillary Thyroid Cancer. Journal of Clinical Oncology, 2018, 36, 438-445.	1.6	102
43	Selective Growth Inhibition in BRAF Mutant Thyroid Cancer by the Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4712-4718.	3.6	95
44	The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E577-E585.	3.6	93
45	Functional Characterization of the T1799-1801del and G1799-1816ins BRAF Mutations in Papillary Thyroid Cancer. Cell Cycle, 2007, 6, 377-379.	2.6	86
46	Genetic Alterations in the Phosphoinositide 3-Kinase/Akt Signaling Pathway Confer Sensitivity of Thyroid Cancer Cells to Therapeutic Targeting of Akt and Mammalian Target of Rapamycin. Cancer Research, 2009, 69, 7311-7319.	0.9	84
47	The BRAFV600E causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle, 2012, 11, 286-295.	2.6	84
48	Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. Endocrine-Related Cancer, 2014, 21, 161-173.	3.1	83
49	Identification of RASAL1 as a Major Tumor Suppressor Gene in Thyroid Cancer. Journal of the National Cancer Institute, 2013, 105, 1617-1627.	6.3	81
50	The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3241-3250.	3.6	80
51	Oxidative stress: a new risk factor for thyroid cancer. Endocrine-Related Cancer, 2012, 19, C7-C11.	3.1	79
52	Clinical utility of RAS mutations in thyroid cancer: a blurred picture now emerging clearer. BMC Medicine, 2016, 14, 12.	5.5	78
53	The Genetic Duet of <i>BRAF</i> V600E and <i>TERT</i> Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer. Journal of Nuclear Medicine, 2020, 61, 177-182.	5.0	78
54	Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. Endocrine-Related Cancer, 2014, 21, 825-830.	3.1	77

#	Article	IF	Citations
55	Association of<i>TERT</i>Promoter Mutation 1,295,228 C>T With<i>BRAF</i>V600E Mutation, Older Patient Age, and Distant Metastasis in Anaplastic Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E632-E637.	3.6	76
56	MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle, 2009, 8, 2122-2124.	2.6	73
57	Recent Advances in Molecular Biology of Thyroid Cancer and Their Clinical Implications. Otolaryngologic Clinics of North America, 2008, 41, 1135-1146.	1.1	70
58	Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. Endocrine-Related Cancer, 2011, 18, 687-697.	3.1	70
59	Potent Inhibition of Thyroid Cancer Cells by the MEK Inhibitor PD0325901 and Its Potentiation by Suppression of the PI3K and NF-ÎºB Pathways. Thyroid, 2008, 18, 853-864.	4.5	67
60	Inhibitory Effects of the Mitogen-Activated Protein Kinase Kinase Inhibitor CI-1040 on the Proliferation and Tumor Growth of Thyroid Cancer Cells with<i>BRAF</i>or<i>RAS</i>Mutations. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4686-4695.	3.6	65
61	Hypermethylation of the DNA mismatch repair gene <i>hMLH1</i> and Its association with lymph node metastasis and T1799A <i>BRAF</i> mutation in patients with papillary thyroid cancer. Cancer, 2008, 113, 247-255.	4.1	65
62	A six-genotype genetic prognostic model for papillary thyroid cancer. Endocrine-Related Cancer, 2017, 24, 41-52.	3.1	63
63	BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. Journal of the National Cancer Institute, 2018, 110, 362-370.	6.3	60
64	Extracellular ATP and cAMP as Paracrine and Interorgan Regulators of Renal Function P2Y Receptors of MDCK Cells: Epithelial Cell Regulation by Extracellular Nucleotides. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 351-354.	1.9	59
65	Detection of Serum Deoxyribonucleic Acid Methylation Markers: A Novel Diagnostic Tool for Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 98-104.	3.6	59
66	The Akt Inhibitor MK2206 Synergizes, but Perifosine Antagonizes, the BRAF^{V600E}Inhibitor PLX4032 and the MEK1/2 Inhibitor AZD6244 in the Inhibition of Thyroid Cancer Cells. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E173-E182.	3.6	58
67	<i>BRAF</i> V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer. Journal of Clinical Oncology, 2018, 36, 2787-2795.	1.6	58
68	IQGAP1 Plays an Important Role in the Invasiveness of Thyroid Cancer. Clinical Cancer Research, 2010, 16, 6009-6018.	7.0	54
69	Hypermethylation of the Pendred syndrome gene SLC26A4 is an early event in thyroid tumorigenesis. Cancer Research, 2003, 63, 2312-5.	0.9	54
70	<i>BRAF</i> mutationâ€selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and geneticâ€potentiated synergism with the mTOR inhibitor temsirolimus. International Journal of Cancer, 2010, 127, 2965-2973.	5.1	52
71	Neuronal migration is mediated by inositol hexakisphosphate kinase 1 via Î±-actinin and focal adhesion kinase. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2036-2041.	7.1	50
72	BRAF Mutation in Papillary Thyroid Microcarcinoma: The Promise of Better Risk Management. Annals of Surgical Oncology, 2009, 16, 801-803.	1.5	47

#	Article	IF	Citations
73	The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). Biochemical and Biophysical Research Communications, 2011, 404, 958-962.	2.1	47
74	Quantitative Shear Wave Velocity Measurement on Acoustic Radiation Force Impulse Elastography for Differential Diagnosis between Benign and Malignant Thyroid Nodules: AÂMeta-analysis. Ultrasound in Medicine and Biology, 2015, 41, 3035-3043.	1.5	47
75	Genetic-guided Risk Assessment and Management of Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2019, 48, 109-124.	3.2	44
76	TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population. Endocrine-Related Cancer, 2015, 22, 901-908.	3.1	42
77	The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer. Clinical Endocrinology, 2005, 63, 263-266.	2.4	41
78	Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer. Endocrine-Related Cancer, 2008, 15, 183-190.	3.1	41
79	Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND. Endocrine-Related Cancer, 2013, 20, 13-22.	3.1	41
80	BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. European Journal of Cancer, 2020, 124, 161-169.	2.8	41
81	Lack of Mutations in the Thyroid Hormone Receptor (TR) Î± and Î² Genes but Frequent Hypermethylation of the TRÎ² Gene in Differentiated Thyroid Tumors. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4766-4770.	3.6	40
82	Mutations in Critical Domains Confer the Human mTOR Gene Strong Tumorigenicity*. Journal of Biological Chemistry, 2013, 288, 6511-6521.	3.4	40
83	<i>BRAF</i> V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3228-3238.	3.6	36
84	Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 Mutations in Thyroid Cancers. Endocrine Pathology, 2011, 22, 97-102.	9.0	33
85	<i>HABP2</i>G534E Mutation in Familial Nonmedullary Thyroid Cancer. Journal of the National Cancer Institute, 2016, 108, djv415.	6.3	33
86	<i>BRAF</i>V600E Mutation and Papillary Thyroid Cancer. JAMA - Journal of the American Medical Association, 2013, 310, 535.	7.4	32
87	Activities of multiple cancer-related pathways are associated with<i>BRAF</i>mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells. Cell Cycle, 2014, 13, 208-219.	2.6	31
88	Uncommon <i>TERT</i> Promoter Mutations in Pediatric Thyroid Cancer. Thyroid, 2016, 26, 235-241.	4.5	31
89	<i>TERT</i> promoter mutation determines apoptotic and therapeutic responses of <i>BRAF</i> -mutant cancers to BRAF and MEK inhibitors: Achilles Heel. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 15846-15851.	7.1	31
90	The sonic hedgehog signaling pathway stimulates anaplastic thyroid cancer cell motility and invasiveness by activating Akt and c-Met. Oncotarget, 2016, 7, 10472-10485.	1.8	31

#	Article	IF	Citations
91	Characterization of the novel tumor-suppressor gene <i>CCDC67</i> in papillary thyroid carcinoma. Oncotarget, 2016, 7, 5830-5841.	1.8	30
92	DKK3 is a potential tumor suppressor gene in papillary thyroid carcinoma. Endocrine-Related Cancer, 2013, 20, 507-514.	3.1	29
93	Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 962-971.	3.6	29
94	Induction of Sodium/Iodide Symporter (NIS) Expression and Radioiodine Uptake in Non-Thyroid Cancer Cells. PLoS ONE, 2012, 7, e31729.	2.5	28
95	<i>REC8</i>is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer. Oncotarget, 2015, 6, 39211-39224.	1.8	26
96	Simultaneous suppression of the MAP kinase and NF-ÎºB pathways provides a robust therapeutic potential for thyroid cancer. Cancer Letters, 2015, 368, 46-53.	7.2	25
97	<i>BRAF</i>^{V600E}Mutation and Papillary Thyroid Cancer: Chicken or Egg?. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2295-2298.	3.6	24
98	Identification and characterization of two novel oncogenic mTOR mutations. Oncogene, 2019, 38, 5211-5226.	5.9	24
99	Induction of Heparanase-1 Expression by Mutant B-Raf Kinase: Role of GA Binding Protein in Heparanase-1 Promoter Activation. Neoplasia, 2010, 12, 946-956.	5.3	23
100	Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis. Thyroid, 2015, 25, 1097-1105.	4.5	20
101	Multiple aspects of male germ cell development and interactions with Sertoli cells require inositol hexakisphosphate kinase-1. Scientific Reports, 2018, 8, 7039.	3.3	19
102	Absence of Germline Mutations in Genes within the MAP Kinase Pathway in Familial Nonmedullary Thyroid Cancer. Cell Cycle, 2006, 5, 2036-2039.	2.6	18
103	<i>BRAF</i> Mutation and Thyroid Cancer Recurrence. Journal of Clinical Oncology, 2015, 33, 2482-2483.	1.6	18
104	Single Nucleotide Polymorphism rs17849071 G/T in the PIK3CA Gene Is Inversely Associated with Follicular Thyroid Cancer and PIK3CA Amplification. PLoS ONE, 2012, 7, e49192.	2.5	17
105	Acoustic Radiation Force Impulse Elastography in the Diagnosis of Thyroid Nodules: Useful or Not Useful?. Ultrasound in Medicine and Biology, 2015, 41, 2581-2593.	1.5	17
106	Induction of Thyroid Gene Expression and Radioiodine Uptake in Melanoma Cells: Novel Therapeutic Implications. PLoS ONE, 2009, 4, e6200.	2.5	17
107	Inositol hexakisphosphate kinase 3 promotes focal adhesion turnover via interactions with dynein intermediate chain 2. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3278-3287.	7.1	14
108	UPF1 reduces C9orf72 HRE-induced neurotoxicity in the absence of nonsense-mediated decay dysfunction. Cell Reports, 2021, 34, 108925.	6.4	14

#	Article	IF	Citations
109	Genetic-Targeted Therapy of Thyroid Cancer: A Real Promise. Thyroid, 2009, 19, 805-809.	4.5	13
110	Therapeutic targeting of FOS in mutant <i>TERT</i> cancers through removing TERT suppression of apoptosis via regulating <i>survivin</i> and <i>TRAIL-R2</i>. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	13
111	Association of Cigarette Smoking with Aberrant Methylation of the Tumor Suppressor Gene RAR?2 in Papillary Thyroid Cancer. Frontiers in Endocrinology, 2011, 2, 99.	3.5	12
112	Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data. PLoS ONE, 2016, 11, e0159235.	2.5	12
113	Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness. Oncotarget, 2017, 8, 900-914.	1.8	12
114	Mutational analysis of the GNA11, MMP27, FGD1, TRRAP and GRM3 genes in thyroid cancer. Oncology Letters, 2013, 6, 437-441.	1.8	11
115	Decreased breast cancer-specific mortality risk in patients with a history of thyroid cancer. PLoS ONE, 2019, 14, e0221093.	2.5	11
116	Epigenetic genes regulated by the BRAFV600E signaling are associated with alterations in the methylation and expression of tumor suppressor genes and patient survival in melanoma. Biochemical and Biophysical Research Communications, 2012, 425, 45-50.	2.1	10
117	Molecular Aberrance in Papillary Thyroid Microcarcinoma Bearing High Aggressiveness: Identifying a â€œTibetan Mastiff Dogâ€•From Puppies. Journal of Cellular Biochemistry, 2016, 117, 1491-1496.	2.6	10
118	Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients. BMC Cancer, 2021, 21, 543.	2.6	10
119	Identifying Genetic Alterations in Poorly Differentiated Thyroid Cancer: A Rewarding Pursuit. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4661-4664.	3.6	9
120	Letter re: Uncommon Mutation but Common Amplifications of thePIK3CAGene in Thyroid Tumors. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5509-5509.	3.6	8
121	[Comments on the Ito et al. article (Endocr J. 2008 Oct 8. Epub ahead of print)] The Lack of Clinicopathological Correlation of BRAF Mutation in Papillary Thyroid Cancer Needs to Be Interpreted with Caution. Endocrine Journal, 2009, 56, 305-306.	1.6	5
122	<i>BRAF</i>V600E Mutation and Papillary Thyroid Cancerâ€"In Reply. JAMA - Journal of the American Medical Association, 2013, 310, 534.	7.4	5
123	RASAL1 in Thyroid Cancer: Promise From a New Friend. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3619-3621.	3.6	4
124	Stage II Differentiated Thyroid Cancer Is a High-Risk Disease in Patients <45/55 Years Old. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4941-4948.	3.6	3
125	BRAF mutation in thyroid carcinogenesis and its clinical implications. Current Opinion in Endocrinology, Diabetes and Obesity, 2006, 13, 455-459.	0.6	2
126	Reply to M. Melo et al. Journal of Clinical Oncology, 2018, 36, 1457-1458.	1.6	2

#	Article	IF	Citations
127	Entering an Era of Precision Management of Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2019, 48, xvii-xviii.	3.2	2
128	Reply to C. Bal et al. Journal of Clinical Oncology, 2015, 33, 2483-2484.	1.6	1
129	Diagnostic and Prognostic Molecular Markers in Thyroid Cancer. , 2016, , 281-292.		1
130	Reply to M. Melo et al. Journal of Clinical Oncology, 2015, 33, 668-669.	1.6	0
131	Response. Journal of the National Cancer Institute, 2016, 108, djw124.	6.3	0
132	When Somatic Mutations Are Associated With a Higher Aggressive Behaviorâ€"A Story of Announced Evidenceâ€"Reply. JAMA Oncology, 2017, 3, 1428.	7.1	0
133	Genetic and Epigenetic Alterations in the MAP Kinase and PI3K/Akt Pathways in Thyroid Cancer. , 2011, , 27-38.		0
134	Response to Letter to the Editor from Boucai and Tuttle: â€œBRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancerâ€. Journal of Clinical Endocrinology and Metabolism, 2022, , .	3.6	0